Tao Zhang

List of Publications by Year in descending order

20 papers	551 citations	623734 14 h-index	752698 20 g-index
21 all docs	21 docs citations	21 times ranked	743 citing authors

#	Article	IF	Citations
1	Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer. Nature Communications, 2019, 10, 2701.	12.8	82
2	OSI-930: A Novel Selective Inhibitor of Kit and Kinase Insert Domain Receptor Tyrosine Kinases with Antitumor Activity in Mouse Xenograft Models. Cancer Research, 2006, 66, 1015-1024.	0.9	69
3	Design and synthesis of selective degraders of EGFRL858R/T790M mutant. European Journal of Medicinal Chemistry, 2020, 192, 112199.	5.5	59
4	Discovery of JND3229 as a New EGFR^{C797S} Mutant Inhibitor with In Vivo Monodrug Efficacy. ACS Medicinal Chemistry Letters, 2018, 9, 1123-1127.	2.8	46
5	Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Molecular Cancer, 2020, 19, 90.	19.2	44
6	Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFR^{L858R/T790M/C797S}. ACS Medicinal Chemistry Letters, 2019, 10, 869-873.	2.8	39
7	Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFR^{L858R/T790M/C797S}). Journal of Medicinal Chemistry, 2019, 62, 7302-7308.	6.4	35
8	Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. Journal of Medicinal Chemistry, 2016, 59, 7111-7124.	6.4	22
9	Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs. ACS Medicinal Chemistry Letters, 2021, 12, 82-87.	2.8	22
10	Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. Journal of Medicinal Chemistry, 2022, 65, 6840-6858.	6.4	20
11	LSâ€106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo. Cancer Science, 2022, 113, 709-720.	3.9	19
12	DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo. Acta Pharmacologica Sinica, 2016, 37, 398-407.	6.1	18
13	C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis. Acta Pharmacologica Sinica, 2019, 40, 823-832.	6.1	18
14	Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. European Journal of Medicinal Chemistry, 2020, 190, 112092.	5.5	16
15	Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R. Acta Pharmacologica Sinica, 2018, 39, 1768-1776.	6.1	10
16	2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	9.6	10
17	Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR^{T790M/C797S} Mutants. ACS Medicinal Chemistry Letters, 2022, 13, 196-202.	2.8	8
18	Discovery of 1,3â€Diarylâ€pyridones as Potent <scp>VEGFR</scp>â€2 Inhibitors: Design, Synthesis, and Biological Evaluation. Chemical Biology and Drug Design, 2016, 87, 694-703.	3.2	5

#	Article	IF	Citations
19	Discovery of N-(3-bromo-1H-indol-5-yl)-quinazolin-4-amine as an effective molecular skeleton to develop reversible/irreversible pan-HER inhibitors. European Journal of Medicinal Chemistry, 2022, 233, 114249.	5.5	5
20	Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Brutonâ€™s tyrosine kinase inhibitors. Acta Pharmacologica Sinica, 2020, 41, 415-422.	6	4